200 related articles for article (PubMed ID: 31485721)
1. Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.
Hodgson A; Jungbluth AA; Katabi N; Xu B; Downes MR
Virchows Arch; 2020 Apr; 476(4):535-542. PubMed ID: 31485721
[TBL] [Abstract][Full Text] [Related]
2. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.
Xu B; Jungbluth AA; Frosina D; Alzumaili B; Aleynick N; Slodkowska E; Higgins K; Ho A; Morris L; Ghossein R; Katabi N
Histopathology; 2019 Nov; 75(5):672-682. PubMed ID: 31237963
[TBL] [Abstract][Full Text] [Related]
3. Basal-subtype bladder tumours show a 'hot' immunophenotype.
Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
[TBL] [Abstract][Full Text] [Related]
4. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
[TBL] [Abstract][Full Text] [Related]
5. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma.
Sharma P; Shen Y; Wen S; Bajorin DF; Reuter VE; Old LJ; Jungbluth AA
Clin Cancer Res; 2006 Sep; 12(18):5442-7. PubMed ID: 17000678
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
[TBL] [Abstract][Full Text] [Related]
8. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ
J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855
[TBL] [Abstract][Full Text] [Related]
9. MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma.
Makise N; Morikawa T; Nakagawa T; Ichimura T; Kawai T; Matsushita H; Kakimi K; Kume H; Homma Y; Fukayama M
Hum Pathol; 2016 Apr; 50():62-9. PubMed ID: 26997439
[TBL] [Abstract][Full Text] [Related]
10. Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors.
Ghadban T; Perez DR; Vashist YK; Bockhorn M; Koenig AM; El Gammal AT; Izbicki JR; Metzger U; Hauswirth F; Frosina D; Jungbluth AA
Eur J Surg Oncol; 2014 Oct; 40(10):1307-12. PubMed ID: 24713551
[TBL] [Abstract][Full Text] [Related]
11. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
12. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett J; Xu B; Downes MR
J Clin Pathol; 2021 Jan; 74(1):53-57. PubMed ID: 32471889
[TBL] [Abstract][Full Text] [Related]
13. Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer.
Hikmet F; Rassy M; Backman M; Méar L; Mattsson JSM; Djureinovic D; Botling J; Brunnström H; Micke P; Lindskog C
Mol Oncol; 2023 Dec; 17(12):2603-2617. PubMed ID: 37341056
[TBL] [Abstract][Full Text] [Related]
14. Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma.
Xie Y; Olkhov-Mitsel E; Alminawi S; Slodkowska E; Downes MR
Pathol Res Pract; 2021 Oct; 226():153607. PubMed ID: 34509050
[TBL] [Abstract][Full Text] [Related]
15. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.
Dyrskjøt L; Zieger K; Kissow Lildal T; Reinert T; Gruselle O; Coche T; Borre M; Ørntoft TF
Br J Cancer; 2012 Jun; 107(1):116-22. PubMed ID: 22596240
[TBL] [Abstract][Full Text] [Related]
16. Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?
Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett JMS; Xu B; Downes MR
Pathol Res Pract; 2020 Nov; 216(11):153200. PubMed ID: 33022560
[TBL] [Abstract][Full Text] [Related]
17. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.
Hemminger JA; Toland AE; Scharschmidt TJ; Mayerson JL; Guttridge DC; Iwenofu OH
Mod Pathol; 2014 Sep; 27(9):1238-45. PubMed ID: 24457462
[TBL] [Abstract][Full Text] [Related]
18. Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.
Lerut E; Van Poppel H; Joniau S; Gruselle O; Coche T; Therasse P
Int J Clin Exp Pathol; 2015; 8(8):9522-32. PubMed ID: 26464715
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous expression of CT10, CT45 and GAGE7 antigens and their prognostic significance in human breast carcinoma.
Zhou X; Yang F; Zhang T; Zhuang R; Sun Y; Fang L; Zhang C; Ma Y; Huang G; Ma F; Song C; Jin B
Jpn J Clin Oncol; 2013 Mar; 43(3):243-50. PubMed ID: 23315387
[TBL] [Abstract][Full Text] [Related]
20. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
